Pfizer Inc. (PFE) Shares Sold by Miles Capital Inc.
Miles Capital Inc. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 20.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,880 shares of the biopharmaceutical company’s stock after selling 7,450 shares during the period. Pfizer comprises 1.2% of Miles Capital Inc.’s portfolio, making the stock its 14th largest holding. Miles Capital Inc.’s holdings in Pfizer were worth $1,261,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Lucas Capital Management purchased a new stake in shares of Pfizer in the fourth quarter valued at about $447,000. Regentatlantic Capital LLC lifted its holdings in shares of Pfizer by 9.7% in the fourth quarter. Regentatlantic Capital LLC now owns 503,318 shares of the biopharmaceutical company’s stock valued at $21,970,000 after purchasing an additional 44,571 shares in the last quarter. Nwam LLC lifted its holdings in shares of Pfizer by 2.5% in the fourth quarter. Nwam LLC now owns 56,191 shares of the biopharmaceutical company’s stock valued at $2,453,000 after purchasing an additional 1,378 shares in the last quarter. Palo Capital Inc. lifted its holdings in shares of Pfizer by 2.3% in the fourth quarter. Palo Capital Inc. now owns 50,217 shares of the biopharmaceutical company’s stock valued at $2,192,000 after purchasing an additional 1,130 shares in the last quarter. Finally, Carnick & Kubik Group LLC lifted its holdings in shares of Pfizer by 14.0% in the fourth quarter. Carnick & Kubik Group LLC now owns 164,657 shares of the biopharmaceutical company’s stock valued at $7,187,000 after purchasing an additional 20,159 shares in the last quarter. 69.17% of the stock is currently owned by hedge funds and other institutional investors.
In related news, insider Mikael Dolsten sold 100,471 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $43.56, for a total transaction of $4,376,516.76. Following the completion of the transaction, the insider now owns 390,097 shares of the company’s stock, valued at $16,992,625.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Pfizer Inc purchased 50,000 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average cost of $17.00 per share, with a total value of $850,000.00. The disclosure for this purchase can be found here. Insiders have sold 288,726 shares of company stock valued at $12,534,617 in the last ninety days. 0.09% of the stock is currently owned by company insiders.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.75 by $0.10. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The firm had revenue of $13.12 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same quarter in the prior year, the business posted $0.77 earnings per share. Pfizer’s revenue for the quarter was up 1.6% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.89 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 10th will be given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 3.50%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is 48.00%.
Several analysts have issued reports on the stock. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Barclays reissued a “hold” rating and issued a $41.00 price objective on shares of Pfizer in a research report on Thursday, May 9th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $46.00 price objective on shares of Pfizer in a research report on Friday, April 19th. Bank of America boosted their price objective on shares of Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research report on Monday, April 1st. Finally, ValuEngine lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Fourteen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $45.83.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.